Mast Therapeutics Inc (NYSEMKT:MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle …
Roth Capital’s healthcare analyst Michael Higgins weighed in with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), after hosting an investor meeting with a Key Opinion …
Roth Capital’s healthcare analyst Michael Higgins weighed in today with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), ahead of the 4th Annual Sickle …
In a research report issued today, Cowen analyst Ritu Baral maintained an Outperform rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), while no price …
In a research report issued today, Roth Capital analyst Michael Higgins reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) with a …
In a research report released today, Canaccord analyst John Newman reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX) with a $3.00 …
Roth Capital’s healthcare analyst Michael Higgins came out with a research report on Mast Therapeutics Inc (NYSEMKT:MSTX), after the company announced the initiation of enrollment into …
Canaccord Genuity’s healthcare analyst John Newman weighed in today with a few insights on Mast Therapeutics Inc (NYSEMKT:MSTX), as the company recently announced that, in a …